ArticleCancer discovery2022
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.
- Targeting p53 pathways: mechanisms, structures, and advances in therapy.Signal transduction and targeted therapy · 2023Pooled it
- Clonal heterogeneity in human pancreatic ductal adenocarcinoma and its impact on tumor progression.Nature genetics · 2026Article
- Hypoxia-induced metastatic heterogeneity in pancreatic cancer.Nature communications · 2026Article
- Amplification of MED30 at chromosome 8q24 reprograms MYC binding to low-affinity oncogenic enhancers in cancer cells.Cell reports · 2026Article
- Immunomodulation of Pancreatic Cancer via Inhibition of SUMOylation and the CD155/TIGIT Pathway.Molecular cancer therapeutics · 2026Article
- PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity.Science advances · 2026Article
- KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers.Molecular cancer · 2026Review
- Transcriptomic Plasticity Is a Hallmark of Metastatic Pancreatic Cancer.Cancer research · 2026Article
- Adipogenic transdifferentiation reprograms EMT-high PDAC cells into a post-mitotic adipocyte-like state and limits metastasis.Cell death & disease · 2026Article
- Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2026Article
- SMAD4 induces opposite effects on metastatic growth from pancreatic tumors depending on the organ of residence.Nature cancer · 2025Article
- Hypoxia-induced metastatic heterogeneity in pancreatic cancer.Research square · 2025Article
- Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer.Science signaling · 2025Article
- Reprogramming the tumor microenvironment with c-MYC-based gene circuit platform to enhance specific cancer immunotherapy.Nature communications · 2025Article
- TFAP2A enhances tumor stemness and promotes metastasis in pancreatic ductal adenocarcinoma.iScience · 2025Article
- Experimental models of pancreas cancer: what has been the impact for precision medicine?The Journal of clinical investigation · 2025Review
- Metastatic heterogeneity in pancreatic cancer: mechanisms and opportunities for targeted intervention.The Journal of clinical investigation · 2025Review
- PUS7 promotes the progression of pancreatic cancer by interacting ANLN to activate MYC pathway.Molecular and cellular biochemistry · 2025Article
- Article
- Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 9 institutions in 2 countries.
Ravikanth Maddipati *Department of Internal Medicine and Children's Research Institute, UT Southwestern Medical Center, Dallas, Texas. Ravikanth.Maddipati@UTsouthwestern.edu bstanger@upenn.edu.
Robert J Norgard *Division of Gastroenterology, Department of Medicine, Penn Pancreatic Cancer Research Center and Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania.
Timour Baslan *Cancer Biology and Genetics Program, Sloan Kettering Institute, New York, New York.
Komal S RathiDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Amy ZhangPanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Asal SaeidDepartment of Internal Medicine and Children's Research Institute, UT Southwestern Medical Center, Dallas, Texas.
Taku HigashiharaDepartment of Internal Medicine and Children's Research Institute, UT Southwestern Medical Center, Dallas, Texas.
Feng WuDepartment of Internal Medicine and Children's Research Institute, UT Southwestern Medical Center, Dallas, Texas.
Angad KumarDepartment of Internal Medicine and Children's Research Institute, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-9535-3620
Valli AnnamalaiDepartment of Internal Medicine and Children's Research Institute, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-8404-1613
Saurav BhattacharyaDepartment of Internal Medicine and Children's Research Institute, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-6461-6862
Pichai RamanDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Christian A AdkissonDepartment of Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
Jason R PitarresiDivision of Gastroenterology, Department of Medicine, Penn Pancreatic Cancer Research Center and Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0001-9549-4768
Maximilian D WengynDivision of Gastroenterology, Department of Medicine, Penn Pancreatic Cancer Research Center and Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania.
Taiji YamazoeDivision of Gastroenterology, Department of Medicine, Penn Pancreatic Cancer Research Center and Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania.
Jinyang LiDivision of Gastroenterology, Department of Medicine, Penn Pancreatic Cancer Research Center and Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0001-8125-6603
David BalliDivision of Gastroenterology, Department of Medicine, Penn Pancreatic Cancer Research Center and Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania.
Michael J LaRiviereDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0002-1662-5086
Tuong-Vi C NgoHarold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-1400-8463
Ian W FolkertDivision of Gastroenterology, Department of Medicine, Penn Pancreatic Cancer Research Center and Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania.
Ian D MillsteinDivision of Gastroenterology, Department of Medicine, Penn Pancreatic Cancer Research Center and Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0002-8253-7412
Jonathan BermeoCancer Biology and Genetics Program, Sloan Kettering Institute, New York, New York.ORCID 0000-0002-9553-9222
Erica L CarpenterDivision of Hematology/Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
John C McAuliffeDepartment of Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
Maja H OktayDepartment of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
Rolf A BrekkenHarold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0003-2704-2377
Scott W LoweCancer Biology and Genetics Program, Sloan Kettering Institute, New York, New York.ORCID 0000-0002-5284-9650
Christine A Iacobuzio-DonahueThe David M. Rubenstein Center for Pancreatic Cancer Research, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-4672-3023
Faiyaz NottaPanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Ben Z StangerDivision of Gastroenterology, Department of Medicine, Penn Pancreatic Cancer Research Center and Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania. Ravikanth.Maddipati@UTsouthwestern.edu bstanger@upenn.edu.ORCID 0000-0003-0410-4037
Southwestern Medical Center · USUPMC Hillman Cancer Center · USAlbert Einstein College of Medicine · USChildren's Hospital of Philadelphia · USHospital of the University of Pennsylvania · USKettering University · USMemorial Sloan Kettering Cancer Center · USOntario Institute for Cancer Research · CAUniversity of Pennsylvania · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTRANSGENIC AND CHIMERIC MOUSE COREP30DK050306 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI REBECCA G WELLS · 1997 to 2026
$32.5MMolecular Determinants and Therapeutic Consequences of Immune Heterogeneity in CancerR01CA229803 · NCI · UNIVERSITY OF PENNSYLVANIA · PI STANGER, BEN Z · 2018 to 2022
$3.7MTraining of Surgeons for Studies of the Tumor MicroenvironmentT32CA200561 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI MCAULIFFE, JOHN · 2015 to 2024
$2.7MThe role of progenitor cells in pancreatic acinar renewal and pre-malignant progressionK08DK109492 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI MADDIPATI, RAVIKANTH · 2017 to 2020
$676kDissecting the oncogenic and pro-metastatic roles of PTHLH-mediated calcium signaling in pancreatic cancerK99CA252153 · NCI · UNIVERSITY OF PENNSYLVANIA · PI PITARRESI, JASON R. · 2021 to 2022
$275kThe role of p120ctn in PDAC epithelial-to-mesenchymal transition and metastasisF32CA221094 · NCI · UNIVERSITY OF PENNSYLVANIA · PI PITARRESI, JASON R. · 2017 to 2018
$115kCalcium-signaling induced epithelial-mesenchymal plasticity in pancreatic cancerF31CA236269 · NCI · UNIVERSITY OF PENNSYLVANIA · PI NORGARD, ROBERT · 2019 to 2020
$78kCIHR 388785NCI NIH HHS F31 CA236269NCI NIH HHS F32 CA221094NCI NIH HHS K99 CA252153NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA229803NCI NIH HHS T32 CA200561NIDDK NIH HHS K08 DK109492NIDDK NIH HHS P30 DK050306
Abstract
The degree of metastatic disease varies widely among patients with cancer and affects clinical outcomes. However, the biological and functional differences that drive the extent of metastasis are poorly understood. We analyzed primary tumors and paired metastases using a multifluorescent lineage-labeled mouse model of pancreatic ductal adenocarcinoma (PDAC)-a tumor type in which most patients present with metastases. Genomic and transcriptomic analysis revealed an association between metastatic burden and gene amplification or transcriptional upregulation of
Indexed as
Gene Expression Regulation, NeoplasticGenes, mycNeoplasm MetastasisAdenocarcinomaAnimalsCarcinoma, Pancreatic DuctalDisease Models, AnimalHumansMicePancreatic Neoplasms
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.